Scientists have met to advise South Africa’s government on its next steps after a study suggested the dominant local coronavirus variant may reduce protective antibodies from Pfizer’s COVID-19 vaccine by two-thirds. The laboratory study, published in the New England Journal of Medicine, is another worry for the country hardest-hit by the pandemic on the African continent after it placed AstraZeneca vaccinations on hold earlier this month. Although its implications on the real-world efficacy of Pfizer’s vaccine are not yet clear, the study comes after clinical trial data on the AstraZeneca, Johnson & Johnson (J&J) and Novavax vaccines showed reduced efficacy against the more contagious 501Y.V2 variant, first identified late last year.
SOURCE: REUTERS AFRICA
More Stories
Joshua Baraka is Ugandan Music’s Next Big Thing
Design for Human Rights
A Landmark Exhibition Celebrating the Global Impact of Modern and Contemporary African Fashions
Seven Striking Images by Africa’s New Creative Wave
Broken Chord, Sadler’s Wells Review – Sublime Music for the Tale of a South African Choir
Kinshasa’s Street Artists Raise Issues about Globalisation and Economic Plunder
Africa’s Leading Tourist Attraction 2023 Nominees
Lagosians will Proudly Tell You there’s No Party like a Lagos Party
If You Are Looking to Set Up an Office Remotely, South Africa has It All
Luxury Places to Stay in Zanzibar for a Memorable Vacation on the Island
Accelerating and Scaling Priority Infrastructure Development in Africa
Case Studies: Strategising for a New Era of African Trade